Source: Virtual Congress 2021 – Advances in diagnosis, treatment and clinical management of nontuberculous mycobacterial disease



Rating:

Share or cite this content

Citations should be made in the following way:
E. Vladimirova (??????, Russian Federation), S. Evgeny (??????, Russian Federation), Z. Anna (??????, Russian Federation), D. Svetlana (??????, Russian Federation). Adverse reactions in the treatment of patients with non-tuberculous pulmonary mycobacteriosis.. 3085

Member's Comments

No comment yet.

Related content which might interest you: Adverse reactions to the tuberculosis treatment Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001 Adverse events during treatment of nontuberculous mycobacterial lung disease: do they really matter? Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis Year: 2018 Adverse events in the treatment of multidrug-resistant tuberculosis Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 The frequency of cases of hepatotoxic reactions in first diagnosed patients with pulmonary tuberculosis Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria Year: 2018 Clinical analysisof patients with pulmonary nontuberculous mycobacterial disease complicated with pneumothorax Source: Annual Congress 2013 –Non-tuberculous mycobacteria: clinical management Year: 2013 Adverse effects of treatment in HIV-associated tuberculosis patients in Iran Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts Year: 2011 Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy Source: Eur Respir J 2005; 25: 324-328 Year: 2005 Respiratory infections associated with nontuberculous mycobacteria in non-HIV patients Source: Eur Respir J 2006; 28: 1211-1215 Year: 2006 Treatment outcomes of pulmonary tuberculosis cases in Izmit/Turkey Source: Eur Respir J 2004; 24: Suppl. 48, 651s Year: 2004 Cavitary formation in non-tuberculous mycobacterial infection is the significant risk for development to chronic pulmonary aspergillosis Source: International Congress 2014 – Cells, biofilms and biomarkers in respiratory infections Year: 2014 CT patterns of pulmonary sarcoidosis are associated with prognosis and complication of chronic pulmonary aspergillosis or non-tuberculous mycobacteria Source: International Congress 2019 – Sarcoidosis: a multifaceted disease that is difficult to manage Year: 2019 Disseminated nontuberculous infections with Mycobacterium genavense during sarcoidosis Source: Eur Respir Rev 2009; 18: 299-301 Year: 2009 Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma Source: Eur Respir J 2011; 37: 865-872 Year: 2011 Treatment of pulmonary NTM infection: can it be done? Source: Annual Congress 2007 - Nontuberculous mycobacteria (NTM): a slow-growing challenge Year: 2007 Treatment outcomes of non tuberculous mycobacterial (NTM) pulmonary disease. Multicenter study Source: Virtual Congress 2020 – Non-tuberculous mycobacteria and latent tuberculosis infection Year: 2020 Adverse reactions of tuberculosis treatment in pacients with and without associated digestive disorders Source: Eur Respir J 2003; 22: Suppl. 45, 522s Year: 2003 Management of pulmonary nontuberculous mycobacteria disease Source: Eur Respir Monogr 2018; 81: 222-237 Year: 2018 Monitoring of antituberculous drugs adverse events during the treatment of multidrug-resistant pulmonary tuberculosis Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Cure rates in nontuberculous mycobacterial pulmonary disease Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019